Researchers analyzed more than 2,000 C. diff infections to identify the link between certain strains and certain adverse events.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Of all C. diff cases, 17.7 percent resulted in severe disease, 4.9 percent resulted in a severe outcome and 2.7 percent resulted in 14-day mortality.
Researchers found the NAP1 strain to be the most common, accounting for 28.4 percent of all infections, followed by NAP4 (10.2 percent) and NAP11 (9.1 percent).
Additionally, the NAP1 strain was the strain most likely to cause severe disease, severe outcome and 14-day mortality.
Researchers suggest strategies to reduce NAP1 infection, including antimicrobial stewardship programs and reduced fluoroquinolone use, may help reduce mortality rates.
More Articles on Infection Control:
Children Experiencing More Resistant Bacterial Infections
Gut Bacteria Linked to Late-Onset Sepsis in Neonates
14 Recent Infection Control Findings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
